Allurion Technologies, Inc. ( (ALUR) ) has released its Q4 earnings. Here is a breakdown of the information Allurion Technologies, Inc. presented to its investors.
Allurion Technologies, Inc., a company focused on combating obesity through innovative weight loss solutions, including the Allurion Gastric Balloon, has reported its financial results for the fourth quarter and full year of 2024. The company operates in the healthcare sector, providing a unique, non-surgical weight loss platform.
In the latest earnings report, Allurion announced a fourth-quarter revenue of $5.6 million and a full-year revenue of $32.1 million. The company highlighted key achievements, including the optimization of muscle mass with low-dose GLP-1s and the clearance to resume sales in France. The company also reported a significant decrease in operating expenses by 39% in the fourth quarter compared to the previous year, despite incurring one-time restructuring charges.
Key financial metrics revealed a gross profit of $2.5 million for the fourth quarter, with a gross profit margin of 45%. The company experienced a loss from operations of $17.1 million for the quarter, which was an improvement from the previous year’s loss. Allurion’s strategic initiatives, such as the AUDACITY FDA clinical trial and the launch of a next-generation Allurion Balloon, are expected to drive future growth. The company anticipates a revenue of approximately $30 million in 2025, with a substantial reduction in operating expenses.
Looking ahead, Allurion’s management remains optimistic about the company’s future prospects. With recent financings expected to support operations through potential FDA approval in 2026, the company is poised to enhance its market position and achieve profitability. The ongoing studies and strategic focus on innovative solutions are set to propel Allurion’s growth in the coming years.